Status:
ACTIVE_NOT_RECRUITING
India HIV-CervCa Project
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Collaborating Sponsors:
Tata Memorial Hospital
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV Positive
HIV Negative
Eligibility:
FEMALE
18+ years
Brief Summary
The investigators propose to prospectively study the difference in treatment (CTRT) completion and toxicities between HIV positive and HIV negative women in India with locally advanced cervical cancer...
Detailed Description
This study will compare chemoradiation completion rates for cervical cancer in two groups, women with HIV and women without HIV. The investigators will also be analyzing tumor tissue for tumor infiltr...
Eligibility Criteria
Inclusion
- patients with newly biopsy proven squamous carcinoma or adenocarcinoma of the uterine cervix, FIGO stage IB2-IIIB in whom curative CTRT is planned
- Karnofsky performance status ≥ 70
- Patients with lower paraortic lymph nodes (below the level of L2 vertebra)
- patients diagnosed with cervical cancer whom also HIV positive or HIV negative
Exclusion
- patients with active tuberculosis
Key Trial Info
Start Date :
February 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2026
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT07167069
Start Date
February 9 2021
End Date
May 1 2026
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tata Memorial Hospital
Mumbai, Maharashtra, India, 400012